In an elderly patient with dementia and insomnia refractory to melatonin, is low‑dose trazodone or mirtazapine the preferred treatment?

Neither Trazodone nor Mirtazapine is Strongly Recommended, but Trazodone Has More Supporting Evidence

Based on current guidelines and evidence, trazodone 50 mg at bedtime is the more appropriate choice between these two options for insomnia in dementia patients, though the evidence base remains limited and both agents carry significant concerns. 1

Guideline Recommendations Against Both Agents

The 2019 VA/DoD guidelines explicitly advise against trazodone for chronic insomnia disorder 1. The guideline found that trazodone showed no differences in sleep efficiency or discontinuation rates compared to placebo, and while it improved subjective sleep quality, it failed to improve objective measures like sleep onset latency, total sleep time, or wake after sleep onset. The work group concluded that "the low-quality evidence supporting the efficacy of trazodone was outweighed by its adverse effect profile" 1.

No guidelines specifically address mirtazapine for insomnia, as it has not been adequately studied for this indication 2.

Evidence Specific to Dementia Populations

Trazodone in Dementia

Despite guideline recommendations against general use, trazodone has demonstrated some efficacy specifically in dementia patients with insomnia:

• A Cochrane systematic review found that trazodone 50 mg significantly improved total nocturnal sleep time by 42.5 minutes (95% CI 0.9 to 84.0) and sleep efficiency by 8.53% (95% CI 1.9 to 15.1) in patients with moderate-to-severe Alzheimer's disease 3
• No serious adverse effects were reported in this trial 3
• Real-world data from long-term care facilities showed trazodone was effective in >90% of older adults with dementia, though falls occurred in 30% of users 4
• An observational study found 65.7% effectiveness for sleep disorders in dementia patients 5

Mirtazapine in Dementia

The evidence for mirtazapine in dementia-related insomnia is negative:

• A randomized, double-blind, placebo-controlled trial of mirtazapine 15 mg in Alzheimer's patients showed no improvement in nocturnal sleep duration or efficiency 6
• Mirtazapine actually worsened daytime sleepiness without improving nighttime sleep 6
• The study concluded there were "no significant therapeutic effects" and found "evidence of worsening of daytime sleep patterns" 6

Safety Considerations Critical in Dementia

Trazodone Safety Profile

• Falls are the most frequent adverse event (30% in long-term care) 4
• Common side effects include dizziness, sedation, headache, nausea 7
• QTc prolongation possible but less concerning at low doses 8
• Recent comparative safety data shows trazodone has lower mortality and dementia progression risk than quetiapine 9

Mirtazapine Safety Profile

• Significant somnolence (54% vs 18% placebo) leading to discontinuation in 10.4% 10
• Weight gain (7.5% gained ≥7% body weight vs 0% placebo) 10
• Increased appetite in 17% 10
• QTc prolongation at higher doses 10
• Orthostatic hypotension risk due to H1 and alpha-1 receptor antagonism 10
• Comparative safety data shows higher dementia rates than trazodone 9

Clinical Algorithm for This Patient

Given melatonin failure in your dementia patient with insomnia:

1. First-line pharmacologic choice: Trazodone 50 mg at bedtime

   • Start at 25 mg if frail or high fall risk
   • Titrate to 50 mg after 3-5 days if tolerated
   • Monitor for orthostatic hypotension and falls closely
   • Reassess efficacy after 2 weeks

2. Avoid mirtazapine as next step given:

   • Negative trial data in Alzheimer's patients 6
   • Worsening daytime sleepiness without nighttime benefit 6
   • Higher dementia progression risk compared to trazodone 9

3. If trazodone fails or is not tolerated, consider:

   • Dual orexin receptor antagonists (suvorexant, lemborexant) 11
   • Low-dose doxepin (3-6 mg) - has evidence in older adults 2
   • Avoid quetiapine - significantly higher mortality, dementia progression, and falls versus trazodone 9

Critical Caveats

• The evidence base for both agents in dementia-related insomnia is weak, with trazodone having only one small positive trial 3
• Non-pharmacologic interventions should be optimized first (sleep hygiene, light therapy, activity scheduling), though you've already tried melatonin
• All sedative-hypnotics increase fall risk in elderly patients with dementia - ensure fall precautions are in place 4
• Short-term use is preferable - reassess need regularly rather than indefinite continuation
• The 2025 comparative safety study provides the most recent high-quality evidence showing trazodone has superior safety to both mirtazapine and quetiapine in older adults 9

The choice of trazodone over mirtazapine is based on: (1) positive RCT data specifically in Alzheimer's patients 3, (2) negative RCT data for mirtazapine in the same population 6, and (3) superior safety profile including lower mortality and dementia progression risk 9.